LaunchTrends: Entyvio (US) (Wave 3) | 2015

LaunchTrends: Entyvio Wave 3 (US) measures the impact of this novel agent on the moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD) market one year following launch. The report evaluates physicians’ current awareness and familiarity with vedolizumab, its advantages and disadvantages compared with currently available therapies, the current and anticipated usage of vedolizumab, and promotional activity of vedolizumab.

Login to access report

launch Related Market Assessment Reports